Brexit could lead to longer waiting times for new medicines, warn experts

The UK's influence over regulation could be reduced and waiting times for new drugs and medical devices to become available increased, warn scientists

Leaving the EU could mean it takes several months longer for new drugs and medical devices to become available in the UK, and reduce Britain's influence in how such products are regulated, experts have warned.

At present, the European Medicines Agency (EMA), which approves new medicines and medical devices across Europe is based in London.